Highlights Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Real-time Estimate Cboe BZX Other stock markets 12:18:15 14/05/2024 am IST			5-day change	1st Jan Change
43 ^USD	+2.42%		-12.01%	-28.25%

09/05	Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing	MT
08/05	UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises	07/05	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M	07/05	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	26/04	MT
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	26/04	CI
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	27/02	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02	CI
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	27/02	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
North American Morning Briefing : Rate Doubts Keep -2-	06/02	DJ
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application	26/01	CI
Apellis says EU regulator panel may not back its eye disease drug	14/12	RE
Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union	14/12	CI
Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI	11/12	CI
Apellis Pharmaceuticals Shares Rise on Updates for US Prescribing Information for Syfovre	02/12	MT
Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Rises	01/11	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q3 Revenue $110.4M	01/11	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
Apellis Pharmaceuticals, Inc. Announces the Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE®? (pegcetacoplan Injection) for Geographic Atrophy (GA)	20/23/20	CI
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G	17/23/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Highlights

Filters